Clinical Trials Logo

Clinical Trial Summary

Severe depression is devastating for those affected and is often associated with significant risk of suicide. Electroconvulsive therapy (ECT) is a highly effective acute treatment for severe depression, but its use and acceptability are limited by cognitive side effects. Of these, retrograde memory loss is most concerning, and can be long-term. The introduction of ultrabrief right unilateral (UBRUL) ECT into clinical practice has been an important step in reducing the risk of memory impairment, but significant deficits still occur. A new form of UBRUL ECT which utilises a Frontoparietal electrode placement represents a further development. Preliminary data suggest that Frontoparietal UBRUL has good efficacy and less cognitive side effects than UBRUL given using the conventional Temporoparietal electrode placement. Designed as a pivotal trial, this protocol will be the first RCT comparing these two forms of ECT, producing the rigorous efficacy and safety data required to change clinical practice/policy. This is a multicentre, parallel group RCT with 1:1 allocation ratio between Frontoparietal (intervention) and Temporoparietal (comparator) forms of UBRUL ECT. Participation will involve receiving randomised acute ECT under blinded conditions during the randomised acute treatment period (typically around 4 weeks), then completion of a 24-week follow-up period which commences after the cessation of all acute ECT. The study protocol aims to provide 12 randomised acute ECT treatments, though the number of treatments (and hence the length of the randomised acute treatment period) can be adjusted by the participant's own treating/admitting psychiatrist according to their clinical judgement.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05402657
Study type Interventional
Source The George Institute
Contact Rita Barreiros
Phone +61 2 9065 9107
Email raft-ect.study@unsw.edu.au
Status Recruiting
Phase N/A
Start date March 22, 2023
Completion date July 2025

See also
  Status Clinical Trial Phase
Completed NCT03256162 - Ketamine as an Adjunctive Therapy for Major Depression Phase 1
Completed NCT01944293 - Ketamine for Suicidality in Bipolar Depression Phase 1/Phase 2
Recruiting NCT01441505 - A Study of Ketamine as an Antidepressant Phase 2
Active, not recruiting NCT03487926 - Microglial Activation in Inflammatory Bowel Disease
Recruiting NCT04939649 - Ketamine as an Adjunctive Therapy for Major Depression (2) Phase 3
Recruiting NCT05028738 - Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety N/A
Recruiting NCT03646058 - Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode Phase 3
Not yet recruiting NCT06117397 - A Text Messaging Intervention to Reduce Perinatal Depression Risk N/A
Completed NCT03735576 - Cognitive Behavioural Therapy for the Treatment of Late Life Depression N/A
Recruiting NCT04999553 - Left vs. Right Non-Inferiority Trial N/A
Completed NCT03716869 - Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder N/A
Recruiting NCT02824081 - Neuroinflammation, Serotonin, Impulsivity and Suicide N/A
Terminated NCT01099592 - Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression Phase 4
Completed NCT03752853 - Stress Systems and Psychotherapy in Depression N/A
Recruiting NCT04480918 - University of Iowa Interventional Psychiatry Service Patient Registry
Recruiting NCT04130958 - Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics N/A
Completed NCT03190772 - The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation N/A
Recruiting NCT04832750 - Depression-Reduction by Accelerated Personalized NeuroModulation and Its Effects on Sleep
Terminated NCT02839798 - NeoSync TMS Treatment for Bipolar I Depression Phase 2
Completed NCT00852592 - Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial Phase 3